Masako Asayama

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2020 · 926 citations · Full text

Medicine, Oncology, Pharmacology +17

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

Kohei Shitara, Takeharu Yamanaka, Tadamichi Denda et al. · Annals of Oncology · 2018 · 87 citations · Full text

Medicine, Oncology, Pharmacology +11

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).

Shota Fukuoka, Hiroki Hara, Naoki Takahashi et al. · Journal of Clinical Oncology · 2019 · 69 citations

Medicine, Oncology, Pharmacology +16

A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma

Takahiro Horimatsu, Norisuke Nakayama, Toshikazu Moriwaki et al. · International Journal of Clinical Oncology · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Ingesting 500 ml of Polyethylene Glycol Solution During Capsule Endoscopy Improves the Image Quality and Completion Rate to the Cecum

Hiroki Endo, Yasuyuki Kondo, Masahiko Inamori et al. · Digestive Diseases and Sciences · 2008 · 41 citations

Medicine, Surgery, Diagnostic Imaging +6